ESMO World Congress on Gastrointestinal Cancer | Conference

Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC

July 3rd 2020

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma

July 3rd 2020

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

Wainberg Weighs in on Favorable Frontline Activity With NALIRIFOX Regimen in Pancreatic Cancer

July 3rd 2020

Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.

EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors

July 3rd 2020

EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.

Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer

July 2nd 2020

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Irinotecan Monotherapy Shows Similar Activity, Improved Safety as Chemo Combo in Advanced Gallbladder Cancer

July 2nd 2020

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.

Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer

July 2nd 2020

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Infigratinib Under Investigation in FGFR2-Altered Advanced Cholangiocarcinoma

July 2nd 2020

Ghassan K. Abou-Alfa, MD, discusses the design and aim of the PROOF trial in advanced cholangiocarcinoma.

Dr. Abou-Alfa on Key Eligibility Criteria for the PROOF Trial in Cholangiocarcinoma

July 2nd 2020

Ghassan K. Abou-Alfa, MD, discusses key eligibility criteria for the phase 3 PROOF trial in cholangiocarcinoma.

Maintenance Olaparib Maintains Benefit in Metastatic Pancreatic Cancer, Regardless of Age

July 2nd 2020

The safety and efficacy of maintenance olaparib in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial.

Real-World Data Indicate Favorable Efficacy With Nivolumab in Advanced Gastric Cancer

July 2nd 2020

Yu Sunakawa, MD, PhD, further discusses the early real-world data from the DELIVER trial with nivolumab in patients with gastric/GEJ cancer and provided insight into what future analyses will examine.

Efficacy With Entrectinib in NTRK+ GI Cancers Indicates a Need for More Molecular Testing

July 1st 2020

Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.

Durvalumab/Tremelimumab Combo Could Expand Frontline Options in Advanced HCC

July 1st 2020

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.

Frontline NALIRIFOX Regimen Shows Promising Activity, Tolerability in Pancreatic Cancer

July 1st 2020

The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

Atezolizumab/Bevacizumab Shows Comparable Activity in Older Patients With Advanced HCC

July 1st 2020

The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.

Dr. Patel on the Role of Entrectinib in Gastrointestinal Malignancies

July 1st 2020

Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.

Nivolumab Demonstrates Survival and Safety Benefit in Frontline HCC With Longer Follow-Up

July 1st 2020

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from the long-term analysis of the CheckMate-459 trial in advanced hepatocellular carcinoma.

Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC

July 1st 2020

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC

June 22nd 2018

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

TAS-102 Benefit Consistent in Real-World Study for mCRC

June 22nd 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.